一种对低氧反应的单原子索诺酶用于向索诺催化疗法,用于缓解动脉样硬化斑块
Qiaofei Chen1, Guotao Yuan1,2,3, Zhiwen Liu1,4
1Department of Cardiology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|September 23, 2025
概括
这项研究引入了一种新的单原子催化剂 (SMC-HA) 用于声催化疗法 (SCT). 通过向M1巨细胞,减少斑块负担,促进病变回归,SMC-HA有效治疗动脉样硬化.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 动脉样硬化带来了重大的健康挑战,需要先进的治疗策略.
- 声触媒疗法 (SCT) 显示出对非侵入性动脉样硬化治疗的希望,但需要有效的声敏剂.
- 优化斑块微环境,平衡诸如H2O2之类的有益因素与减轻缺氧,对于SCT疗效至关重要.
研究的目的:
- 开发一个微环境可调节的单原子索诺酶系统,用于增强SCT.
- 创建一个新型的单原子催化剂 (SMC) 功能化为有针对性的交付.
- 评估SMC-HA在临床前动脉样硬化模型中的疗效.
主要方法:
- 合成了一种单原子催化剂 (SMC),使用MOF衍生的前体热解和离子植入.
- 功能化SMC与氨酸 (HA) 用于向M1巨细胞的向输送.
- 用SMC-HA和应用超声波 (US) 治疗ApoE-/- 动脉样硬化的小鼠模型.
主要成果:
- SMC-HA证明了原子精确的四个协调的活性点.
- 实现了SMC-HA向M1巨细胞的向输送.
- 超声波激活的SMC-HA有效地消除了M1巨细胞,减少了斑块负担并促进了病变回归.
结论:
- SMC-HA 作为一种先进的声敏化剂,用于有效的SCT.
- 通过SMC-HA介导的SCT代表了治疗动脉样硬化斑块治疗的有前途的治疗策略.
- 这种方法提炼了损伤的微环境,以改善治疗结果.
相关概念视频
Peroxisomes
20.0K
Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
20.0K
Oxidative Cleavage of Alkenes: Ozonolysis
12.8K
In ozonolysis, ozone is used to cleave a carbon–carbon double bond to form aldehydes and ketones, or carboxylic acids, depending on the work-up.
Ozone is a symmetrical bent molecule stabilized by a resonance structure.
Ozone is a symmetrical bent molecule stabilized by a resonance structure.
12.8K
Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
12.6K
Alkenes are converted to 1,2-diols or glycols through a process called dihydroxylation. It involves the addition of two hydroxyl groups across the double bond with two different stereochemical approaches, namely anti and syn. Dihydroxylation using osmium tetroxide progresses with syn stereochemistry.
12.6K
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
3.8K
Catalytic hydrogenation of alkenes is a transition-metal catalyzed reduction of the double bond using molecular hydrogen to give alkanes. The mode of hydrogen addition follows syn stereochemistry.
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
3.8K


